NextSource Biotechnology announced that a new 5mg strength of Gleostine (lomustine) capsules has been approved by the Food and Drug Administration (FDA) and is now commercially available.

Gleostine is indicated to treat primary and metastatic brain tumors, in patients who have already received appropriate surgery and radiotherapy; and indicated as secondary therapy for Hodgkin’s disease in combination with other approved drugs in patients who relapse while being treated or who fail primary therapy.

RELATED: Geography May be an Independent Risk in HPV Oropharyngeal Cancer Prevalence

Gleostine is an alkylating agent that is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Gleostine is already available in 10mg, 40mg, and 100mg dosage strengths. The new 5mg strength capsules are also available in 5-count bottles.

For more information call (855) 672-2468 or visit